Eric L. Smith

Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma.

Multiple myeloma (MM) is monitored using bone marrow-based minimal residual disease (MRD) assays, which provide high sensitivity but require repeated invasive sampling and are limited to a single anatomical site. Cell-free DNA (cfDNA) offers a minimally invasive alternative, yet most cfDNA approaches rely on prior tumo...